CPT code 65778 covers placement of an amniotic membrane on the ocular surface, a therapeutic ophthalmic procedure used to promote corneal and conjunctival healing. Nationally, this procedure matters because it addresses refractory epithelial defects, surface inflammation, and other conditions where biologic membrane support can reduce morbidity and improve visual outcomes. Use of amniotic membrane techniques has increased as clinicians seek alternatives to more invasive procedures and as product availability and coverage policies evolve.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find an overview of how CPT code 65778 is defined clinically, typical sites of service, common billing modifiers, and where national payers tend to focus their medical necessity and coverage policies. The publication also summarizes benchmark considerations such as coding nuances, claim bundling risks, and documentation elements that commonly affect payment adjudication.

This summary provides clinicians, billing staff, and policy analysts with concise context on the clinical purpose of CPT code 65778, the payer landscape nationally, and the types of benchmarks and policy details to review when preparing or auditing claims for amniotic membrane placement on the ocular surface.